Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutacimig in congenital factor VII deficiency
ISRCTN16472226Phase 2Recruiting
- Sponsor
- Hemab Therapeutics
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of sutacimig in congenital factor VII deficiency (2 arms), sponsored by Hemab Therapeutics. Primary endpoint: Treatment-emergent adverse events and safety assessments. Started Oct 2025; status: recruiting.
02
Drugs
sutacimig
03
Conditions
congenital factor VII deficiency
Beyond the preview
Go deeper on ISRCTN16472226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16472226.